Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
mohammed Abdul Salaam
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed with schizophrenia according to ICD 10 with a duration of illness more than two years, stable without active symptomatology and on anti psychotic treatment
Exclusion criteria
Exclusion criteria: Patients who are not given consent and who are on on any CNS drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure clinical utility of memantine effectiveness in schizophrenia patients along with second generation antipsychotics in ameliorating the cognitive symptoms of schizophreniaTimepoint: Baseline: The cognitive functions at baseline will be assessed using Addenbrooke’s cognitive examination (ACE) scale. Memantine will be added to the ongoing treatment as an adjunctive At the end of study: ACE scale will be repeated at the end of eight weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in cognitive symptoms score through ACE scaleTimepoint: At the end of 8 weeks cognitive assessment is done using ACE scale | — |
Countries
India
Contacts
Public ContactMohammed Abdul Salaam
Konaseema institute of medical sciences and research foundation
Outcome results
None listed